Disitamab Vedotin Clinical Trials
7 recruitingDrug
Phase 26Phase 11Phase 31
Showing 1–7 of 7 trials
Recruiting
Phase 3
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Gastric Carcinoma
RemeGen Co., Ltd.555 enrolled1 locationNCT07315750
Recruiting
Phase 2
A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery
Upper Urinary Tract Urothelial Carcinoma
Peking University First Hospital60 enrolled1 locationNCT06210490
Recruiting
Phase 2
Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
Breast Cancer
RemeGen Co., Ltd.40 enrolled1 locationNCT06642545
Recruiting
Phase 2
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Metastatic Gastric CancerUnresectable Gastric CarcinomaHER2-positive Gastric Cancer
Qilu Hospital of Shandong University110 enrolled20 locationsNCT06730373
Recruiting
Phase 1Phase 2
Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
Metastatic HER2 Positive Gastroesophageal Junction Cancer
Zhejiang Cancer Hospital90 enrolled1 locationNCT06650332
Recruiting
Phase 2
A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer
Cervical Cancer
RemeGen Co., Ltd.116 enrolled12 locationsNCT06155396
Recruiting
Phase 2
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Gastric CancerGastroesophageal Junction Adenocarcinoma
RemeGen Co., Ltd.90 enrolled11 locationsNCT06155383